Financials in USD. Standardized financial statements.
A compact view of how ImmunoGen, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $108.78M | $69.86M | $132.30M | $82.27M | $53.82M | $115.45M | $48.63M | $60.00M | $85.54M | $59.90M |
| Revenue Growth? | +55.7% | -47.2% | +60.8% | +52.9% | -53.4% | +137.4% | -19.0% | -29.9% | +42.8% | 0.0% |
| Cost of Revenue? | $176,000 | $0 | $114.59M | $114.52M | $173.89M | $139.74M | $141.31M | $146.91M | $111.77M | $106.96M |
| Gross Profit? | $108.61M | $69.86M | $17.71M | -$32.25M | -$120.07M | -$24.29M | -$92.68M | -$86.91M | -$26.23M | -$47.06M |
| Gross Margin? | +99.8% | +100.0% | +13.4% | -39.2% | -223.1% | -21.0% | -190.6% | -144.9% | -30.7% | -78.6% |
| Operating Expenses? | $329.50M | $194.93M | $153.19M | $153.01M | $210.60M | $173.65M | $43.54M | $183.83M | $140.00M | $131.43M |
| Operating Income? | -$220.89M | -$125.07M | -$135.49M | -$92.17M | -$160.48M | -$58.98M | -$131.21M | -$123.83M | -$54.45M | -$71.53M |
| EBITDA? | -$215.76M | -$124.19M | -$19.68M | -$65.73M | -$153.45M | -$55.60M | -$125.20M | -$123.53M | -$55.30M | -$71.53M |
| Income Before Tax | -$221.71M | -$139.30M | -$44.37M | -$104.13M | -$167.87M | -$96.01M | -$156.73M | -$143.66M | -$60.74M | -$71.36M |
| Income Tax Expense | $1.22M | $0 | $22.31M | $17.96M | $0 | $0 | $0 | $0 | $0 | -$167,000 |
| Net Income? | -$222.93M | -$139.30M | -$66.68M | -$122.09M | -$167.87M | -$96.01M | -$156.73M | -$143.66M | -$60.74M | -$71.36M |
| EPS? | $-0.88 | $-1.08 | $-0.38 | $-0.82 | $-1.20 | $-0.98 | $-1.80 | $-1.65 | $-0.71 | $-0.83 |
| Diluted EPS? | $-0.88 | $-1.08 | $-0.38 | $-0.82 | $-1.20 | $-0.98 | $-1.80 | $-1.65 | $-0.71 | $-0.83 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality